TIGERLILY + LABCORP CLINICAL SITE LISTENING SUMMIT (VIRTUAL)
2 NOVEMBER 2022, 11AM TO 12:30PM EST
“I AM INCLUDED” How Sites Are Including Diverse Patients
Inclusive National Clinical Sites Led in Unity, Diversely and Equitably Driven
Tigerlily + Labcorp Clinical Site Listening Summit (Virtual)
Join us for an innovative Clinical Site Listening Summit on Wednesday 2 November 2022 at 11 am EST for a conversation with stakeholders to include patient experts, Black and Latino healthcare professionals, and investigators from Historically Black Colleges and Universities (HBCUs), National Cancer Institute (NCI) Cancer Centers and community health centers as we formulate healthcare solutions and best practices that will put the patient first.
These best practices will inform a strategic framework that will increase the acceleration of life-saving clinical trials in underserved communities while considering internal and external partnerships. Learn valuable insights shared by a panel of experts across the industry and HBCUs on how to make sites more inclusive for our patients! Jointly hosted by Tigerlily Foundation and Labcorp Drug Development.
Meet the Panelists Patient Experts
Shonte Drakeford, MSN, CRNP, AGNP-C
Patient Expert, Metastatic Breast Cancer Patient Advocate
Shonte Drakeford is a 38 year-old Washington, D.C. native, Nurse Practitioner, Army wife, Farmer, German Shepard mama, and a friend to all. She received her Bachelor of Science in Nursing at Bowie State University (May 2007) and a Master of Science in Nursing as an Adult-Gerontology Nurse Practitioner (June 2017) at Ball State University. She was diagnosed with Stage IV Triple Negative Metastatic Breast Cancer in 2015 at the age of 31, as her initial diagnosis. She also has a genetic mutation for colon cancer. She started cancer detection early, at the age of 25 but unfortunately was denied and delayed early detection diagnostics for 6 years before being diagnosed. She understands treatment will be lifelong and this condition is terminal.
Shonte continues to educate & advocate using the most evidenced-based research of Metastatic Breast Cancer care. She has partnered with organizations such as local MBC support groups, METAvivor Board Member – ThisisMBC Project, Tigerlily Foundation – Angel Advocate, Living Beyond Breast Cancer (LBBC) – Hear My Voice Advocate, Project Life MBC Board member, Our MBC LIFE podcast, Metastatic Breast Cancer Alliance, Broad Institute Of MIT and Harvard – Count Me in Project, The Centers for Disease Control and Prevention (CDC), FDA (Federal Drug Administration) and served on advisory boards for pharmaceutical companies. Shonte was most recently recognized for being one of the Top DC’s Nurses by Because of Them We Can.
Dr. Angelo D. Moore, PhD, MSN, RN, NE-BC
Assistant Director, Community Outreach, Engagement, and Equity, Duke Cancer Institute, Durham, NC
Dr. Angelo D. Moore is the Assistant Director, Community Outreach, Engagement, and Equity (COEE), Duke Cancer Institute, where he provides overall direction, coordination, and implementation DCI’s community impact-designed projects to reduce cancer outcomes disparities in the DCI community and across its Catchment Area. The mission is to reduce cancer disparities and improve population health in DCI catchment area for historically marginalized and medically underserved populations.
He serves on multiple local, state, national committees and boards to include organizations such as the American Cancer Society National Navigation Roundtable Steering Committee, and National Black Nurses Association Board of Directors.
He received his BSN in 1995 from Winston-Salem State University, MSN in 2002 from Uniformed Services University of the Health Sciences, and PhD in 2010 from the University of North Carolina at Chapel Hill. He served 25 years in the U.S. Army and retired as a Lieutenant Colonel.
Dr. Kim F. Rhoads, MD, MS, MPH, FACS
Associate Professor, Epidemiology & Biostatistics, Affiliate Philip R. Lee Institute for Health Policy Studies; Associate Director, Community Engagement, Helen Diller Family Comprehensive Cancer Center, UCSF School of Medicine; Founder, Umoja Health Partners, San Fransisco, CA
Dr. Rhoads is an associate professor of epidemiology and biostatistics at UCSF, with formal training as a general and colorectal surgeon. She has additional training in basic science, health care disparities and health policy research. She also trained as a community organizer at the Center for Third World Organizing during medical school. In her current role, she serves as the Associate Director for Community Engagement at the UCSF Cancer Center and as the Director of Umoja Health, a community run COVID-19 testing and vaccination initiative where all the services are provided by the community partners in Oakland. Dr. Rhoads earned her medical degree at UCSF, a Masters of Health Science at UC Berkeley and a Masters of Public Health at Harvard.
Dr. Rajbir Singh, MBBS
Executive Director, Precision Medicine & Health Equity Trials Design Clinical and Translational Research Center, Center for Women’s Health Research; Assistant Professor, Internal Medicine, Meharry Medical College, Nashville, TN
Dr. Rajbir Singh is the Executive Director for Precision Medicine & Health Equity Trials Design at Meharry Medical College and serves as the Principal Investigator (PI) of IGNITE trials at Meharry and site PI for the Phase III for STAR CRN.
Dr. Singh works closely with the community engagement core at Meharry having led and coordinated more than 50 clinical trials including oncology clinical trials and pharmaceutical trials, including the most recent Novovax clinical trial for the COVID-19 vaccine. As the lead on these trials, he is responsible for day-to-day oversight and running of the ongoing trial activities across the project life cycle. He is currently the PI of multiple genomic trials: Implementing Genomics in Practice (IGNITE) Consortium trials, Genomic Testing to Understand and Address Renal Disease Disparities In US (GAURDD-US) testing participants for APOL 1 gene and A Depression and Opioid Pragmatic Trials in PGX (ADOPT PGX), testing for CYP2C19 and CYP2D6 genes for targeted therapy recommendations. He is associated with other trials like Electronic Medical Records and Genomics (EMERGE) to have genomics implemented via EMR. His core mission is to increase the participation of under-represented or under-served groups impacted by health disparities in clinical research for health equity.
Dr. Kedar Kirtane, MD
Assistant Member, Physician Director for Engagement of Special
Populations for Clinical Trials, Department of Head and Neck-Endocrine Oncology, Moffitt Cancer
Center, Tampa, FL
Dr. Kirtane is an Assistant Member at Moffitt Cancer Center in the Department of Head and
Neck-Endocrine Oncology. He is also the Physician Director for the Engagement of Special
Populations in Clinical Trials.
Dr. Kirtane received his MD degree from the University of Florida College of Medicine. He
completed an Internal Medicine Residency at Duke University Medical Center. Dr. Kirtane
completed a Hematology/Oncology Fellowship at the University of Washington and a Post-
Doctoral Fellowship in Oncology at the Fred Hutchinson Cancer Research Center in Seattle,
Washington. His clinical focus is patients with head & neck and endocrine cancers. His research interests include
healthcare disparities, patient-reported outcomes, and developing cellular immunotherapies for solid tumor
Evelyn González, MA
Senior Director, Office of Community Outreach, Fox Chase Cancer Center,
Temple Health, Philadelphia, PA
Ms. González is a public health advocate with over 30 years’ experience focused on health disparities and health equity. As Senior Director for the Office of Community Outreach at Fox Chase Cancer Center, an NCI-designated Comprehensive Cancer Center, she leads the community engagement programs, which include bilingual cancer education, onsite and mobile cancer screening, and supports institutional research endeavors. Recognized as a passionate leader, Ms. González has been honored for her outstanding commitment to the health of Latinos by the American Cancer Society and Susan G. Komen. Ms. González is also an advisory board member of the PA Department of Health’s Office of Health Equity and a board of director for the PA Breast Cancer Coalition.
Ms. González is an author and educator who received her Master’s degree in health advocacy from Sarah Lawrence College in New York. Her professional career includes work in reproductive healthcare, maternal and child health, genetics, cardiovascular disease, community health workers and oncology.
Journalist, Cancer Survivor, Patient Advocate, President/Executive Director, The Latino Cancer Institute, San Jose, CA
Ysabel Duron is a pioneering, award-winning Latina journalist (ret), a cancer survivor, and for the last 22 years, a leader in Latinx/Hispanic cancer education and advocacy. In that time, she launched two local Latino cancer service agencies in Silicon Valley.
In 2017, Ms. Duron inaugurated The Latino Cancer Institute (TLCI), a nationwide network dedicated to developing best practice programs to enhance the work of Latino community service agencies, collaborates with the global cancer research community, and drives policy to diminish the Latino cancer burden. Duron serves on the IRB of the NIH/All of Us Research Program; is an appointee to the California Institute for Regenerative Medicine, the taxpayer funded stem cell agency; and was recently appointed to the newly launched ACS National Breast Cancer Roundtable which officially debuted October 25, 2022. Duron is a published co-author with a number of academic institutions.
Dr. Carla Williams
Associate Professor of Medicine & Public Health, Interim Director, Howard University Cancer Center, Washington D.C.
Dr. Carla Williams received her Ph.D. in clinical psychology from Howard University. She is currently Associate Professor of Medicine and Public Health and Interim Director of the Howard University Cancer Center. Her research work centers around understanding and reducing cancer-related health disparities and engaging communities that have not been adequately represented in research. Dr. Williams works with community health leaders to promote individual adoption of healthy lifestyle behaviors as well as population-level change in the environment, health policies, and health systems.
Since 2010, Dr. Williams’ collaborative research efforts have resulted in the expansion of her role to function as an Executive Scientist. In this capacity, she helps to build research teams within and across institutions to promote collaborative research. Most recently, she has worked to develop a combined didactic and practice-based course that builds skills for community engagement as a key discipline in public health, health care research, and health policy.
Dr. Priscilla Pemu, MD MS, FACP
Professor and Vice Chair, Research, Department of Medicine; Associate Dean Clinical Research, Director, Clinical Research Center, Morehouse School of Medicine, Atlanta, GA
Dr. Isagani Chico
Vice President, Global Therapeutic Head for Oncology, Labcorp Clinical Development Services, Labcorp Drug Development
Dr. Isagani (Gani) M. Chico, MD, is Vice President and Global Therapeutic Head for Oncology, Labcorp Clinical Development Services, based in Gaithersburg, Maryland. Gani has >35 years of experience in Oncology clinical drug development from small and medium sized biotechnology companies, CROs and the FDA, focused on planning and execution global Oncology clinical development projects from early phase to post approval, leadership of cross-functional strategic teams within medical affairs and clinical development organizations, and management of pharmaceutical, academic and regulatory interactions.
Gani earned his medical Degree from the University of the Philippines, completed his Internal Medicine residency at the Cook County Hospital in Chicago, Medical Oncology fellowship training at the National Institutes of Health in Bethesda, MD. At Labcorp Oncology, Gani leads a dedicated global team of >60 oncology physicians with an average of 23 years of academic and industry related clinical experience.
President of Clinical Therapeutic and Regulatory Sciences; Chief Scientific Officer of Labcorp Drug Development
Bill has responsibility for all the scientific, therapeutic, market access & regulatory expertise, patient recruitment, medical device & diagnostics development, Cell & Gene Therapy growth and digital innovation for the clinical trials business. Bill has over 30 years of scientific, drug development and business leadership experience as well as extensive background in international (US, EU, LATAM, APAC) business. Starting his career at Merck, Inc. (MSD) in 1988, he quickly advanced in responsibility, broadening his expertise in global regulatory affairs and driving strategic product development. Starting at Covance in 2012 as Head of Regulatory Affairs, his most recent role was President, Clinical Development & Commercialization Services (2018-2019).
Bill earned his Bachelor of Science degree in biochemistry from Rutgers University and his Doctor of Philosophy in biochemistry and cell biology, jointly conferred by the University of Medicine and Dentistry of NJ and Rutgers University Graduate School.
Founder & CEO, Tigerlily Foundation
Maimah is the Founder/CEO of the Tigerlily Foundation (Tigerlily) and a sixteen-year survivor of breast cancer. On February 28, 2006, at 4:45 p.m., Maimah was diagnosed with Stage 2 triple negative breast cancer. She had no family history and was 32-years old. While undergoing her second round of chemotherapy, she made a promise to God that if she survived, she would create an organization to educate, empower, advocate for and support young women affected by breast cancer. After her second treatment, Tigerlily Foundation was born. Tigerlily provides breast health, educational, empowerment wellness and transformational programs to young women; and works to end disparities of age, stage and color.
Senior Director, Diversity & Inclusion, Site and Patient Engagement, Labcorp Drug Development
Elizabeth is passionate about having adequate representation of populations with disease in clinical trials. She is leading the Diversity & Inclusion in Clinical Trials initiative at Labcorp Drug Development with a focus on making clinical trials more inclusive of diverse participants. Her prior role was Director, Clinical Trial Diversity at GSK, where she successfully led strategies and solutions to enable the enrollment of representative participants in clinical trials. She has extensive experience leading large-scale digital transformation projects, developing transformative business strategies, managing all phases of the project lifecycle from conception through product launch, and has a deep knowledge of pharmaceutical R&D processes.
She is a thought leader and has been invited to speak at numerous conferences on the importance of inclusive clinical research. She has a Bachelor of Science in Statistics from the University of Mumbai and a Master of Science in Computer & Information Sciences from Temple University.